Literature DB >> 8626855

Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas.

M Derwahl1, C Hamacher, D Russo, M Broecker, D Manole, H Schatz, P Kopp, S Filetti.   

Abstract

In toxic thyroid adenomas, mutations in the TSH receptor (TSH-R) gene or the gene encoding the alpha-subunit of the stimulatory guanine nucleotide-binding protein (Gs alpha) have been demonstrated to constitutively activate the cAMP cascade, which subsequently stimulates the growth and function of these tumors. However, the widely varying thyroid phenotypes in patients with TSH-R germline mutations, ranging from only slightly enlarged diffuse to multinodular goiters, suggest that additional mechanisms may be effective in the pathogenesis of toxic adenomas. We have investigated the levels of stimulatory and inhibitory G protein alpha-subunits together with basal and TSH-stimulated adenylate cyclase (AC) activity in toxic adenomas with or without activating mutations and in nodular and extranodular tissues of a toxic goiter due to a germline mutation in the TSH-R gene. Augmented expression of Gs alpha protein was detected in all toxic adenomas, independent of the presence of mutations, and in the nodular tissue of the toxic goiter, but not in the nonnodular hyperplastic tissue of the toxic goiter with the mutated TSH-R. Analogously, the expression of the alpha-subunit of the inhibitory G protein (Gi alpha) was also increased in all adenomas and the nodular tissue of the goiter, but, again, not in the hyperplastic goiter tissue. Basal AC activity was high in all tissues with mutations, but was only slightly increased in adenomas without detected mutations. No correlation was detectable between basal or TSH-stimulated AC activity and the levels of Gs alpha and Gi alpha. Our data suggest that mutational activation of the cAMP cascade may not be sufficient to generate toxic nodules and adenomas, but far more complex mechanisms, including alterations of G protein signaling, may be effective in the pathogenesis of these tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626855     DOI: 10.1210/jcem.81.5.8626855

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Thyrotropin receptor mutations in thyroid diseases.

Authors:  P M Yen
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

Review 2.  Molecular insights into TSH receptor abnormality and thyroid disease.

Authors:  D Russo; F Arturi; E Chiefari; S Filetti
Journal:  J Endocrinol Invest       Date:  1997-01       Impact factor: 4.256

3.  Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.

Authors:  S Hoffmann; K Maschuw; I Hassan; A Wunderlich; S Lingelbach; A Ramaswamy; L C Hofbauer; A Zielke
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

4.  Overexpression of stimulatory G protein alpha-subunit is a hallmark of most human somatotrophic pituitary tumours and is associated with resistance to GH-releasing hormone.

Authors:  C Hamacher; M Bröcker; E F Adams; T Lei; R Fahlbusch; M Buchfelder; M Derwahl
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

5.  Alteration in G proteins and prolactin levels in pituitary after ethanol and estrogen treatment.

Authors:  Kirti Chaturvedi; Dipak K Sarkar
Journal:  Alcohol Clin Exp Res       Date:  2008-03-11       Impact factor: 3.455

6.  The Pathogenic TSH β-subunit Variant C105Vfs114X Causes a Modified Signaling Profile at TSHR.

Authors:  Laura Kalveram; Gunnar Kleinau; Kamila Szymańska; Patrick Scheerer; Adolfo Rivero-Müller; Annette Grüters-Kieslich; Heike Biebermann
Journal:  Int J Mol Sci       Date:  2019-11-07       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.